Sometimes it's good to just rally the troops a bit. While I didn't see anything especially new in Roche's (RHHBY.OB) Investor Day presentations, it was a good reminder as to the depth, breadth, and quality of this Big Pharma's drug and diagnostics pipeline. History says that several of these currently-promising programs will fall by the wayside, and Roche's shares are not quite slam-dunk cheap, but this remains a quality to name to hold in the healthcare space.
Please read more here:
Roche Hosts An Encouraging Investor Day